The PRKRA/PACT Antibody (CAB5417) is a high-quality antibody developed for reliable detection and analysis of target proteins. This antibody, produced in rabbits, is highly specific and reactive with human samples, making it ideal for use in Western blot applications.PRKRA is a key player in the cellular response to viral infections, acting as a regulator of the antiviral immune response. By binding to PRKRA, this antibody allows for the detection and analysis of this important protein in various cell types, facilitating investigations into immune signaling pathways and antiviral defense mechanisms.
This antibody is validated for use in WB, ELISA applications and has demonstrated reactivity against Mouse samples.
Product Name:
PRKRA/PACT Antibody
SKU:
CAB5417
Size:
20μL, 100μL
Reactivity:
Mouse
Conjugate:
Unconjugated
Immunogen:
Recombinant protein (or fragment).This information is considered to be commercially sensitive.
Recommended starting concentration is 1 μg/mL. Please optimize the concentration based on your specific assay requirements.
Synonyms:
RAX, PACT, DYT16, HSD14, PRKRA/PACT
Positive Sample:
Mouse liver
Cellular Localization:
Cytoplasm, Perinuclear Region.
Calculated MW:
34kDa
Observed MW:
35kDa
This gene encodes a protein kinase activated by double-stranded RNA which mediates the effects of interferon in response to viral infection. Mutations in this gene have been associated with dystonia. Alternative splicing results in multiple transcript variants.
Purification Method
Affinity purification
Gene ID
8575
RRID
AB_2766225
Buffer Information
Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS containing 50% glycerol, preserved with proclin300 or sodium azide, pH 7.3.
Western blot analysis of lysates from mouse liver, using PRKRA/PACT Rabbit pAb (CAB5417) at 1:1000 dilution. Secondary antibody: HRP-conjugated Goat anti-Rabbit IgG (H+L) (CABS014) at 1:10000 dilution. Lysates/proteins: 25μg per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit (AbGn00020). Exposure time: 90s.
